Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony patologicznie rak gruczołowy odbytnicy II lub III stopnia zaawansowania
- •Pisemna zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Przerzuty nowotworu do odległych miejsc w organizmie
- •Wcześniejsze leczenie raka odbytnicy
- •Transfuzja krwi w ciągu ostatniego miesiąca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
OHSU Knight Cancer Institute
Portland, United States
Fred Hutch
Seattle, United States
Trial contact
Adel Kardosh, M.D.,Ph.D.
Adel Kardosh, M.D.,Ph.D.
PRINCIPAL_INVESTIGATOR
Stacey Cohen, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.